Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment

about

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment

Item

http://www.wikidata.org/entity/Q37366251

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Sensitivity of imatinib-resist ...... atinib and forskolin treatment

@en

Sensitivity of imatinib-resist ...... tinib and forskolin treatment.

@nl

type

Item

label

Sensitivity of imatinib-resist ...... atinib and forskolin treatment

@en

Sensitivity of imatinib-resist ...... tinib and forskolin treatment.

@nl

prefLabel

Sensitivity of imatinib-resist ...... atinib and forskolin treatment

@en

Sensitivity of imatinib-resist ...... tinib and forskolin treatment.

@nl

P1476

Sensitivity of imatinib-resist ...... atinib and forskolin treatment

@en

P2093

Derrick M Oaxaca

http://www.w3.org/2001/XMLSchema#string

Georgialina Rodriguez

http://www.w3.org/2001/XMLSchema#string

Jeremy A Ross

http://www.w3.org/2001/XMLSchema#string

Joan G Staniswalis

http://www.w3.org/2001/XMLSchema#string

Robert A Kirken

http://www.w3.org/2001/XMLSchema#string

Sun Ah Yang-Reid

http://www.w3.org/2001/XMLSchema#string

P2860

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction

The Hsp90 chaperone complex as a novel target for cancer therapy.

P2888

s13277-016-5179-7

P304

12643-12654

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13277-016-5179-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27444277

http://www.w3.org/2001/XMLSchema#string

P932

5080333

http://www.w3.org/2001/XMLSchema#string